Identification of microRNA signatures in thyroid cancer

Authors

DOI:

https://doi.org/10.14739/mmt.2026.2.350387

Keywords:

thyroid cancer, papillary carcinoma, follicular carcinoma, microRNA, biomarkers

Abstract

Aim: to identify differentially expressed microRNAs (miRNAs) in papillary and follicular thyroid cancer (TC) and to evaluate their potential as diagnostic and prognostic biomarkers.

Materials and methods. Three GEO datasets were analyzed: GSE104006 (20 samples of papillary TC and 6 normal tissues), GSE191117 (50 samples of papillary TC and 50 normal samples), and GSE62054 (17 samples of follicular carcinoma and 8 benign tumors). Differentially expressed miRNAs were identified with |log2FC| >1 and p < 0.05 with subsequent FDR correction DIANA miRPath v. 3 was used to assess signaling pathways, miRNet v. 2.0 to identify target genes, and ShinyGO v. 0.82 for functional annotation. Prognostic significance was evaluated using ENCORI database.

Results. Six miRNAs were selected: hsa-miR-15a-5p, hsa-miR-146b-5p, hsa-miR-199b-5p, hsa-miR-221-5p, hsa-miR-222-3p, and hsa-miR-484. They potentially regulate over 2,000 target genes, including RET, CCND1, TP53, HIF1A, IL6, and IL1B, which are associated with the development and progression of malignant tumors. GEO analysis revealed their involvement in the regulation of metabolism, biosynthesis, protein modification, as well as in the binding functions of transcription factors, DNA, and RNA. Nineteen KEGG signaling pathways were identified, 13 of which are closely associated with carcinogenesis. Prognostic analysis indicated that low expression of hsa-miR-146b-5p and hsa-miR-221-5p correlate with significantly poorer overall survival in TC patients.

Conclusions. The proposed panel of six miRNAs may have significant potential for the differential diagnosis of papillary and follicular thyroid cancer, risk stratification, and prognosis; hsa-miR-146b-5p and hsa-miR-221-5p demonstrated the greatest prognostic value. Further experimental studies are needed for the clinical validation of these biomarkers.

Author Biographies

A. Ya. Pasko, Ivano-Frankivsk National Medical University

MD, PhD, Associate Professor of the Department of Surgical Diseases

V. D. Skrypko, Ivano-Frankivsk National Medical University

MD, PhD, DSc, Professor of the Department of Postgraduate Surgery and Urology

References

  1. Kitahara CM, Schneider AB. Epidemiology of thyroid cancer. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1284-97. doi: https://doi.org/10.1158/1055-9965.EPI-21-1440
    | |
  2. The International Agency for Research on Cancer (IARC). Global Cancer Observatory [Internet]. Who.int. [cited 2026 Jan 14]. Available from: https://gco.iarc.who.int/factsheets/cancers/32-thyroid
  3. Asa SL. The Current Histologic Classification of Thyroid Cancer. Endocrinol Metab Clin North Am. 2019;48(1):1-22. doi: https://doi.org/10.1016/j.ecl.2018.10.001
    | |
  4. Forma A, Kłodnicka K, Pająk W, Flieger J, Teresińska B, Januszewski J, et al. Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies. Int J Mol Sci. 2025;26(11):5173. doi: https://doi.org/10.3390/ijms26115173
    | |
  5. O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018;9:402. doi: https://doi.org/10.3389/fendo.2018.00402
    | |
  6. Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Update on Fundamental Mechanisms of Thyroid Cancer. Front Endocrinol (Lausanne). 2020;11:102. doi: https://doi.org/10.3389/fendo.2020.00102
    | |
  7. Silaghi H, Pop LA, Georgescu CE, Muntean D, Crișan D, Silaghi P, et al. MicroRNA Expression Profiling-Potential Molecular Discrimination of Papillary Thyroid Carcinoma Subtypes. Biomedicines. 2024;12(1):136. doi: https://doi.org/10.3390/biomedicines12010136
    | |
  8. Pasko AY, Skrypko VD. [MicroRNAs as prognostic markers of thyroid carcinoma]. Clinical Endocrinology and Endocrine Surgery. 2025;(2):48-52. Ukrainian. doi: https://doi.org/10.30978/CEES-2025-2-48
  9. Cao S, Yin Y, Hu H, Hong S, He W, Lv W, et al. CircGLIS3 inhibits thyroid cancer invasion and metastasis through miR-146b-3p/AIF1L axis. Cell Oncol (Dordr). 2023;46(6):1777-89. doi: https://doi.org/10.1007/s13402-023-00845-2
    | |
  10. Jia M, Shi Y, Li Z, Lu X, Wang J. MicroRNA-146b-5p as an oncomiR promotes papillary thyroid carcinoma development by targeting CCDC6. Cancer Lett. 2019;443:145-56. doi: https://doi.org/10.1016/j.canlet.2018.11.026
    | |
  11. Silaghi CA, Lozovanu V, Silaghi H, Georgescu RD, Pop C, Dobrean A, et al. The Prognostic Value of MicroRNAs in Thyroid Cancers-A Systematic Review and Meta-Analysis. Cancers (Basel). 2020;12(9):2608. doi: https://doi.org/10.3390/cancers12092608
    | |
  12. Papaioannou M, Chorti AG, Chatzikyriakidou A, Giannoulis K, Bakkar S, Papavramidis TS. MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment. Front Oncol. 2022;11:755097. doi: https://doi.org/10.3389/fonc.2021.755097
    | |

Downloads

Additional Files

Published

2026-06-09

How to Cite

Pasko, A. Y., & Skrypko, V. D. (2026). Identification of microRNA signatures in thyroid cancer. Modern Medical Technology, 18(2), 105–111. https://doi.org/10.14739/mmt.2026.2.350387

Issue

Section

Original research